Dr. Giltnane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 DNA Way
Genentech
South San Francisco, CA 94080Phone+1 650-455-9091
Education & Training
- Vanderbilt University Medical CenterResidency, Pathology-Anatomic and Clinical, 2008 - 2012
- Yale School of MedicineClass of 2008
Certifications & Licensure
- TN State Medical License 2012 - 2017
Publications & Presentations
PubMed
- Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel
Cancer Cell. 2024-12-09 - An Immunofluorescence-Guided Segmentation Model in Hematoxylin and Eosin Images Is Enabled by Tissue Artifact Correction Using a Cycle-Consistent Generative Adversaria...Marcel Wiedenmann, Mariya Barch, Patrick S Chang, Jennifer Giltnane, Tyler Risom
Modern Pathology. 2024-11-01 - 3 citationsAutomated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, Wei Zou, Andries Zijlstra
The Journal of Pathology. 2024-06-01
Grant Support
- Breast Cancer Breakthrough Research AwardDept. of Defense2014–Present
External Links
- LinkedIn https://www.linkedin.com/in/giltnane
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: